The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit
Endothelin-1 (ET-1) induces severe pathologic conditions such as coronary spasm followed by vasospastic angina pectoris and acute myocardial infarction. The related pathophysiologic mechanisms have remained obscure. Endothelin-1 receptor (ET(A) and ET(B)) is reported to couple with several types of...
Saved in:
Published in | Journal of cardiovascular pharmacology Vol. 35; no. 2; p. 203 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.02.2000
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Endothelin-1 (ET-1) induces severe pathologic conditions such as coronary spasm followed by vasospastic angina pectoris and acute myocardial infarction. The related pathophysiologic mechanisms have remained obscure. Endothelin-1 receptor (ET(A) and ET(B)) is reported to couple with several types of G protein-involved pathways that participate in phospholipase C activation and atrial myofibrils organization into sarcomeric units. Here we demonstrate that ET-1 induces histologic and pathologic dysfunction in the rabbit myocardium and that such pathologic events are prevented by the Rho-kinase inhibitor fasudil. Although the bolus injection of ET-1 (1.4 nmol/kg) via the auricular vein of the rabbit induced only transient T-wave elevation, irreversible, severe histologic changes were observed in papillary muscles of the ventricle, and multifocal myocardial necrosis with infiltration of neutrophils and macrophages in the left ventricle occurred. Oral administration of fasudil (10 mg/kg) significantly reduced the occurrence of myocardial injury determinants, whereas conventional Ca2+ channel blockers (nifedipine, diltiazem) and a K+ channel opener (nicorandil; 10 mg/kg, p.o. each) showed a lesser or no effect on such determinants. These results suggest that ET-1 induces severe myocardial dysfunction based not only on the occurrence of vasospastic ischemia but also on its direct effects on the myocardium. |
---|---|
AbstractList | Endothelin-1 (ET-1) induces severe pathologic conditions such as coronary spasm followed by vasospastic angina pectoris and acute myocardial infarction. The related pathophysiologic mechanisms have remained obscure. Endothelin-1 receptor (ET(A) and ET(B)) is reported to couple with several types of G protein-involved pathways that participate in phospholipase C activation and atrial myofibrils organization into sarcomeric units. Here we demonstrate that ET-1 induces histologic and pathologic dysfunction in the rabbit myocardium and that such pathologic events are prevented by the Rho-kinase inhibitor fasudil. Although the bolus injection of ET-1 (1.4 nmol/kg) via the auricular vein of the rabbit induced only transient T-wave elevation, irreversible, severe histologic changes were observed in papillary muscles of the ventricle, and multifocal myocardial necrosis with infiltration of neutrophils and macrophages in the left ventricle occurred. Oral administration of fasudil (10 mg/kg) significantly reduced the occurrence of myocardial injury determinants, whereas conventional Ca2+ channel blockers (nifedipine, diltiazem) and a K+ channel opener (nicorandil; 10 mg/kg, p.o. each) showed a lesser or no effect on such determinants. These results suggest that ET-1 induces severe myocardial dysfunction based not only on the occurrence of vasospastic ischemia but also on its direct effects on the myocardium. |
Author | Sasaki, Y Ikegaki, I Uchida, T Yamamoto, Y |
Author_xml | – sequence: 1 givenname: Y surname: Yamamoto fullname: Yamamoto, Y organization: Institute for Life Science Research, Asahi Chemical Industry, Co., Ltd., Fuji, Shizuoka, Japan – sequence: 2 givenname: I surname: Ikegaki fullname: Ikegaki, I – sequence: 3 givenname: Y surname: Sasaki fullname: Sasaki, Y – sequence: 4 givenname: T surname: Uchida fullname: Uchida, T |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10672851$$D View this record in MEDLINE/PubMed |
BookMark | eNo1UMlOwzAU9KGILvALyD9gsB3bSY6oYpMqcSnn6nkjLolT2QlS_p6UwjvMjEbz5jBrtIh9dAhhRu8ZrcsHOp8shCD8rM5Afq0FWlGmKOFCqCVa53yklAlZqmu0ZFSVvJJshb73jcOn1A8uRPwVImSHQ2yCDkOfsIc82tBeAmbIGD4hxDzgkE3jumBwN_UGkg3Qzm_HMU0z2dE4i_WEXbT90Lg2RMJmH88aJ9Bz9w268tBmd_vHG_Tx_LTfvpLd-8vb9nFHjKRMEiVEYaXmFS2NkcYzyTT1tWdglKmtAGq958ZLDUpVoGUlCwmKljVwU6qab9Ddpfc06s7ZwymFDtJ0-B-A_wAW0GC_ |
CitedBy_id | crossref_primary_10_1161_01_ATV_0000176193_83629_c8 crossref_primary_10_1038_sj_bjp_0704410 crossref_primary_10_1248_yakushi_127_501 crossref_primary_10_1097_00005344_200203000_00001 crossref_primary_10_7554_eLife_74211 crossref_primary_10_1179_174313209X393564 crossref_primary_10_1161_01_ATV_0000105053_46994_5B crossref_primary_10_1016_j_niox_2014_09_002 crossref_primary_10_3995_jstroke_11045 crossref_primary_10_1016_j_pupt_2010_09_001 crossref_primary_10_1159_000051074 crossref_primary_10_1016_j_ejphar_2005_10_018 crossref_primary_10_1111_j_1540_8191_2009_00888_x crossref_primary_10_1254_jjp_87_34 crossref_primary_10_1161_01_RES_0000096650_91688_28 crossref_primary_10_1016_j_bcp_2004_09_016 crossref_primary_10_1007_s00296_008_0792_4 crossref_primary_10_1007_s12975_012_0247_9 crossref_primary_10_1161_01_RES_0000111804_34509_94 crossref_primary_10_1016_S0024_3205_02_02178_1 crossref_primary_10_1097_FJC_0b013e31802df112 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1097/00005344-200002000-00005 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 10672851 |
Genre | Journal Article |
GroupedDBID | --- .-D .55 .GJ .Z2 01R 0R~ 1CY 1J1 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 77Y 7O~ 8L- AAAAV AAHPQ AAIQE AAMTA AARTV AASCR AASOK AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFFNX AFUWQ AGINI AHQNM AHRYX AHVBC AI. AINUH AJIOK AJNWD AJNYG AJZMW ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C N9A NPM N~7 N~B N~M O9- OAG OAH OCUKA ODA OJAPA OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPC OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VH1 VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH YOC ZFV ZGI ZKB ZXP ZZMQN |
ID | FETCH-LOGICAL-c5015-6443d5b2807cc5cf151b0f9f1ac6c9d4a0dff2cf5ba668ab58535a6079a2c7692 |
ISSN | 0160-2446 |
IngestDate | Sat Sep 28 08:36:59 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c5015-6443d5b2807cc5cf151b0f9f1ac6c9d4a0dff2cf5ba668ab58535a6079a2c7692 |
OpenAccessLink | https://doi.org/10.1097/00005344-200002000-00005 |
PMID | 10672851 |
ParticipantIDs | pubmed_primary_10672851 |
PublicationCentury | 2000 |
PublicationDate | 2000-February |
PublicationDateYYYYMMDD | 2000-02-01 |
PublicationDate_xml | – month: 02 year: 2000 text: 2000-February |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of cardiovascular pharmacology |
PublicationTitleAlternate | J Cardiovasc Pharmacol |
PublicationYear | 2000 |
SSID | ssj0014576 |
Score | 1.7382792 |
Snippet | Endothelin-1 (ET-1) induces severe pathologic conditions such as coronary spasm followed by vasospastic angina pectoris and acute myocardial infarction. The... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 203 |
SubjectTerms | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology Animals Cell Movement - drug effects Diltiazem - pharmacology Electrocardiography - drug effects Endothelin-1 - antagonists & inhibitors Enzyme Inhibitors - therapeutic use Heart Ventricles - drug effects Heart Ventricles - pathology Macrophages - physiology Male Microscopy Myocardial Ischemia - pathology Myocardial Ischemia - prevention & control Necrosis Neutrophils - physiology Nicorandil - pharmacology Nifedipine - pharmacology Papillary Muscles - drug effects Papillary Muscles - ultrastructure Rabbits Random Allocation Vasodilator Agents - pharmacology |
Title | The protein kinase inhibitor fasudil protects against ischemic myocardial injury induced by endothelin-1 in the rabbit |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10672851 |
Volume | 35 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLVSkBAbBOX90l2gbqaDnHl4MkuEQBVSqy4Sqayqa3vcDiXTKA-k8DP8KtePeVBaBGwmIzuyEp-TO8fOvceMvdGco0kLWpagtAuULI0nutBxJUpSG2MseWU39A-PxMEs-3SSn4xGPwZZS5u1fKu-X1tX8j-oUhvhaqtk_wHZblBqoHvCl66EMF3_GmNntFA30UXd0AMpqpvzWtKvdBkZXG10_TUKTgyrCM-wJjEY1bSgdSnx8y09yJaucqRuvtDk0oveKK9Jq0bb4ixSofG4TYZcoqSxb9Cz6tfM1kXvid3t2n_GORI1Lvu4b0l5UZ2hPzy7P6gZV6Gpe9tMndca-7TudqeCt8nN_eal4DHJCTGMvt6sJLAsGYZS533we4j31sHcVRFnmeWDlby-Pt5VcK8HyC_mDnrrk5dMvLPtn3uvmG-3XTtsp5jYMHpkN4PCn1RZ7s4u7L5WSBRrPUGv-3jWozYMeWUd4_TM9D67F4CDd55VD9ioanbZncOQarHL9o49gNt9mPY1eqt92IPjAbQP2TfqhsBC8CyEjoUQWAgtCyGwEFoWQs9C8CyEwEKQWxiykNqB7sGz8BGbffwwfX8Qh9M8YpWT5oxJeKc6l9Z9SalcGZKakpvSjFEJVeoMuTYmUSaXKMQEJa1j0xwFL0pMVCHK5DG71Vw21VMGiRR5lWakLkueSV2UiT1Bu0ixQlSY4DP2xE_t6cJbtpy2k_78xp4X7G7P2ZfstqEYUb0iwbmWrx3sPwG8K36w |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+protein+kinase+inhibitor+fasudil+protects+against+ischemic+myocardial+injury+induced+by+endothelin-1+in+the+rabbit&rft.jtitle=Journal+of+cardiovascular+pharmacology&rft.au=Yamamoto%2C+Y&rft.au=Ikegaki%2C+I&rft.au=Sasaki%2C+Y&rft.au=Uchida%2C+T&rft.date=2000-02-01&rft.issn=0160-2446&rft.volume=35&rft.issue=2&rft.spage=203&rft_id=info:doi/10.1097%2F00005344-200002000-00005&rft_id=info%3Apmid%2F10672851&rft_id=info%3Apmid%2F10672851&rft.externalDocID=10672851 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0160-2446&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0160-2446&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0160-2446&client=summon |